

**EXCLUSIVE LICENSING AGREEMENT FOR
IN-HOUSE DEVELOPED MONOCLONAL ANTIBODY FARLETUZUMAB
IN LATIN AMERICA CONCLUDED WITH EUROFARMA LABORATÓRIOS S.A.**

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that its research subsidiary Morphotek, Inc. (Headquarters: Pennsylvania, United States, President and CEO: Nicholas Nicolaides, “Morphotek”) has signed an exclusive licensing agreement with Eurofarma Laboratórios S.A. (Headquarters: São Paulo, Brazil, President: Maurizio Billi, “Eurofarma”) to develop and commercialize the monoclonal antibody farletuzumab (development code: MORAb-003) as a potential anticancer agent in Latin America.

Under the terms of the agreement, Morphotek will receive from Eurofarma an upfront payment as well as

[Notes to editors]

1. About farletuzumab (generic name, development code: MORAb-003)

Farletuzumab is a humanized, IgG1 monoclonal antibody that binds to the folate receptor-alpha (FRA), a folate-binding protein that is reported to be highly expressed on ovarian and several other epithelial cancer cells. Monoclonal antibodies are a type of immunotherapy used to treat cancer that are manmade versions of immune system proteins and can be designed to attack a specific part of a cancer cell. Immunotherapy drugs offer a method of treatment distinct from chemotherapy.

2. About Eurofarma Laboratórios S.A. (Eurofarma)

Founded in 1972, Eurofarma is one of the largest pharmaceutical companies in Brazil, conducting business across 90% of the Latin American market. Eurofarma maintains operating units in Argentina, Bolivia, Brazil, Central America, Chile, Colombia, Peru and Uruguay, and a presence in Mexico and Venezuela. Eurofarma's capabilities span from research and development to clinical trial execution to marketing and sales of in-licensed and wholly owned products. Eurofarma's mission is to promote access to health and quality m ym g ia, from

nd t